Answers are grounded in this paper and cite their sources.
Selective blockade reduces tissue fibrosis in fibrotic diseases, suggesting a safer treatment option.
Selective blockade of latent TGF-β1 activation represents a promising approach for treating a broad range of fibrotic diseases and cancers. By specifically targeting TGF-β1, SOF10 may offer a safer and more effective therapeutic option compared to non-selective TGF-β inhibitors. This strategy has the potential to transform the treatment paradigm for fibrosis-related conditions.
No takes yet. Share an insight, caveat, or question.
Kanamori et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: